Polymyxin B Dosing in Acute Kidney Injury
Polymyxin B does NOT require dose reduction based on creatinine clearance in patients with acute kidney injury. Unlike the outdated FDA label recommendations, current evidence demonstrates that polymyxin B clearance is not significantly influenced by renal function, and standard weight-based dosing should be maintained regardless of creatinine clearance 1.
Key Dosing Recommendations
Standard Dosing Strategy
- Loading dose: 2.0–2.5 mg/kg (or fixed 150–200 mg for patients 50–90 kg) 1, 2
- Maintenance dose: 1.5–3.0 mg/kg/day divided every 12 hours 1
- Alternative fixed dosing: 75 mg every 12 hours after loading dose 2
Critical Distinction from FDA Label
The FDA-approved prescribing information 3 recommends dose reduction "from 15,000 units/kg downward for individuals with kidney impairment." This recommendation is outdated and not supported by pharmacokinetic evidence. Multiple studies demonstrate that polymyxin B plasma concentrations are not influenced by renal function 1, 4.
Evidence Supporting No Dose Adjustment
Polymyxin B undergoes minimal renal elimination. A direct comparison study found no significant difference in polymyxin B exposure (AUC) between patients with normal renal function (CLCR ≥80 mL/min) versus renal insufficiency (CLCR <80 mL/min): 63.5 ± 16.6 mg·h/L versus 56.0 ± 17.5 mg·h/L (P = 0.42) 4. When adjusted for dose, exposures remained comparable (28.6 ± 7.0 versus 29.7 ± 11.2 mg·h/L, P = 0.80) 4.
Population pharmacokinetic modeling confirms that creatinine clearance is not a significant covariate for polymyxin B clearance 5, 2. The drug is primarily eliminated through non-renal mechanisms, with typical clearance of 1.59–1.75 L/h regardless of renal function 5.
Special Considerations in AKI
Renal Replacement Therapy
- Continuous RRT (CRRT): No dose adjustment required 1
- Convective modalities (CVVH, CVVHDF): May require higher maintenance doses due to increased clearance 6
- Intermittent hemodialysis: Standard dosing maintained; polymyxin B is not significantly dialyzed 1
Monitoring Strategy
While dose adjustment is not required, intensive renal monitoring is essential because polymyxin B itself causes nephrotoxicity:
- Baseline assessment: Serum creatinine, BUN, estimated GFR
- Early monitoring: Check renal function within 3 days of initiation 7, 8
- Ongoing surveillance: Daily creatinine during first week, then every 2–3 days 8
- AKI detection: Use KDIGO criteria; median onset is 4 days after starting therapy 8
Risk Factors for Polymyxin B-Induced AKI
Patients at highest risk include those with 8:
- Elevated baseline creatinine or BUN
- Reduced baseline GFR
- Higher body mass index
- Concomitant nephrotoxic agents (aminoglycosides, vancomycin, contrast)
- Multiple comorbidities
Therapeutic Drug Monitoring
TDM is strongly recommended when available to optimize efficacy and minimize toxicity 9, 6, 2. Target steady-state concentrations:
- Average steady-state concentration (Css,avg): ≥2 mg/L for organisms with MIC ≤1 mg/L
- AUC target: 50–100 mg·h/L for optimal efficacy with acceptable nephrotoxicity risk
Common Pitfalls to Avoid
Do not reduce polymyxin B dose based solely on low creatinine clearance – this leads to subtherapeutic exposure and treatment failure 1, 4
Do not confuse polymyxin B with colistin (polymyxin E) – colistin is administered as the prodrug colistimethate and DOES require renal dose adjustment 1
Do not use weight-based dosing >90 kg without TDM – fixed dosing (150 mg load, then 75 mg q12h) may be safer and equally effective 2
Do not ignore fluid status – daily fluid intake significantly affects polymyxin B pharmacokinetics; fluid overload increases volume of distribution and may require dose adjustment 10
Do not delay dose reduction if AKI develops – if creatinine rises significantly during therapy, consider reducing to 50 mg q12h while maintaining treatment 7
Clinical Algorithm
For patients with pre-existing AKI or any creatinine clearance:
- Administer standard loading dose (2.0–2.5 mg/kg or 150–200 mg fixed)
- Continue standard maintenance dosing (1.5–3.0 mg/kg/day divided q12h)
- Monitor renal function closely (baseline, day 3, then every 2–3 days)
- If new or worsening AKI develops during therapy:
- Assess for other nephrotoxic agents and remove if possible
- Consider dose reduction to lower end of range (1.5 mg/kg/day)
- Implement TDM if available
- Do NOT discontinue unless AKI is severe and alternative therapy exists
The key principle: Polymyxin B dosing is based on body weight and infection severity, NOT renal function at baseline. Renal function monitoring is for detecting drug-induced nephrotoxicity, not for initial dose adjustment.